India · Delayed Price · Currency is INR Mono Pharmacare Statistics
Total Valuation
Mono Pharmacare has a market cap or net worth of INR 187.29 million. The enterprise value is 725.21 million.
| Market Cap | 187.29M |
| Enterprise Value | 725.21M |
Important Dates
The last earnings date was Thursday, July 9, 2026.
| Earnings Date | Jul 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mono Pharmacare has 17.67 million shares outstanding. The number of shares has increased by 7.91% in one year.
| Current Share Class | 17.67M |
| Shares Outstanding | 17.67M |
| Shares Change (YoY) | +7.91% |
| Shares Change (QoQ) | +15.82% |
| Owned by Insiders (%) | 56.72% |
| Owned by Institutions (%) | n/a |
| Float | 7.65M |
Valuation Ratios
The trailing PE ratio is 24.37.
| PE Ratio | 24.37 |
| Forward PE | n/a |
| PS Ratio | 0.13 |
| PB Ratio | 0.60 |
| P/TBV Ratio | 0.60 |
| P/FCF Ratio | 31.93 |
| P/OCF Ratio | 27.59 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.99, with an EV/FCF ratio of 123.65.
| EV / Earnings | 87.03 |
| EV / Sales | 0.49 |
| EV / EBITDA | 14.99 |
| EV / EBIT | 15.38 |
| EV / FCF | 123.65 |
Financial Position
The company has a current ratio of 1.92, with a Debt / Equity ratio of 1.76.
| Current Ratio | 1.92 |
| Quick Ratio | 1.01 |
| Debt / Equity | 1.76 |
| Debt / EBITDA | 11.37 |
| Debt / FCF | 93.77 |
| Interest Coverage | 1.31 |
Financial Efficiency
Return on equity (ROE) is 2.73% and return on invested capital (ROIC) is 3.27%.
| Return on Equity (ROE) | 2.73% |
| Return on Assets (ROA) | 2.69% |
| Return on Invested Capital (ROIC) | 3.27% |
| Return on Capital Employed (ROCE) | 8.16% |
| Weighted Average Cost of Capital (WACC) | 3.50% |
| Revenue Per Employee | 12.83M |
| Profits Per Employee | 72,461 |
| Employee Count | 115 |
| Asset Turnover | 1.35 |
| Inventory Turnover | 2.71 |
Taxes
In the past 12 months, Mono Pharmacare has paid 5.89 million in taxes.
| Income Tax | 5.89M |
| Effective Tax Rate | 41.15% |
Stock Price Statistics
The stock price has decreased by -58.51% in the last 52 weeks. The beta is -0.32, so Mono Pharmacare's price volatility has been lower than the market average.
| Beta (5Y) | -0.32 |
| 52-Week Price Change | -58.51% |
| 50-Day Moving Average | 11.78 |
| 200-Day Moving Average | 17.95 |
| Relative Strength Index (RSI) | 40.40 |
| Average Volume (20 Days) | 7,600 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mono Pharmacare had revenue of INR 1.48 billion and earned 8.33 million in profits. Earnings per share was 0.43.
| Revenue | 1.48B |
| Gross Profit | 127.70M |
| Operating Income | 47.16M |
| Pretax Income | 14.32M |
| Net Income | 8.33M |
| EBITDA | 48.39M |
| EBIT | 47.16M |
| Earnings Per Share (EPS) | 0.43 |
Balance Sheet
The company has 12.40 million in cash and 549.96 million in debt, with a net cash position of -537.56 million or -30.42 per share.
| Cash & Cash Equivalents | 12.40M |
| Total Debt | 549.96M |
| Net Cash | -537.56M |
| Net Cash Per Share | -30.42 |
| Equity (Book Value) | 312.56M |
| Book Value Per Share | 15.23 |
| Working Capital | 567.79M |
Cash Flow
In the last 12 months, operating cash flow was 6.79 million and capital expenditures -924,000, giving a free cash flow of 5.87 million.
| Operating Cash Flow | 6.79M |
| Capital Expenditures | -924,000 |
| Depreciation & Amortization | 1.22M |
| Net Borrowing | 45.22M |
| Free Cash Flow | 5.87M |
| FCF Per Share | 0.33 |
Margins
Gross margin is 8.65%, with operating and profit margins of 3.20% and 0.56%.
| Gross Margin | 8.65% |
| Operating Margin | 3.20% |
| Pretax Margin | 0.97% |
| Profit Margin | 0.56% |
| EBITDA Margin | 3.28% |
| EBIT Margin | 3.20% |
| FCF Margin | 0.40% |
Dividends & Yields
Mono Pharmacare does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.91% |
| Shareholder Yield | -7.91% |
| Earnings Yield | 4.45% |
| FCF Yield | 3.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |